Dihexa

Dihexa is a synthetic modified tripeptide derivative with the sequence N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, developed by researchers at Washington State University led by Dr. Joseph Harding and Dr. John Wright. It emerged from structure-activity relationship studies on angiotensin IV analogs and represents a highly potent, orally active nootropic compound.

Dihexa's primary mechanism of action involves augmentation of hepatocyte growth factor (HGF) signaling through its receptor c-Met. It stabilizes the HGF dimer and enhances c-Met receptor activation, triggering downstream signaling cascades (PI3K/Akt, MAPK/ERK) that promote synaptogenesis, neurogenesis, and dendritic spine formation. In some binding assays, Dihexa has demonstrated potency up to 10 million times greater than BDNF at facilitating new synaptic connections, though this comparison requires careful contextual interpretation.

Preclinical research has shown that Dihexa crosses the blood-brain barrier and reverses cognitive deficits in aged and scopolamine-treated rats. In dementia models, it restored performance in spatial learning tasks to levels comparable to young, healthy animals. Studies have demonstrated increased dendritic spine density and enhanced synaptic plasticity in hippocampal neurons. The compound has also shown potential for reversing motor neuron degeneration. Its oral bioavailability and exceptional potency make it one of the most discussed nootropic compounds in the research community, though human clinical trials have not yet been conducted.